What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to formally report Eli Lilly's updated financial guidance for 2017, reaffirm its long-term financial expectations through the end of the decade, and provide initial financial guidance for the upcoming fiscal year 2018. It also informs investors about a teleconference held to discuss these updates.

What are non-GAAP financial measures and why does Lilly use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP-reported results. For Lilly, these typically include amortization of intangibles and other highly variable or unpredictable expenses. The company uses them because they believe these adjusted measures provide a more accurate reflection of ongoing operational performance and facilitate better period-over-period comparisons, helping investors identify underlying business trends.

Should investors rely solely on the non-GAAP financial measures provided by Lilly?

No, investors should not rely solely on non-GAAP financial measures. Lilly explicitly states in the filing that these non-GAAP measures should be considered in addition to, and not as a substitute for or superior to, financial performance measures prepared in accordance with GAAP. Investors should review both GAAP and non-GAAP figures for a comprehensive understanding.

Where can I find the detailed financial guidance and discussion?

The detailed financial guidance and discussion are provided in the press release dated December 13, 2017, which is attached to this 8-K filing as Exhibit 99.1. Investors can refer to this exhibit for the specifics of the updated guidance and the rationale behind it.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) issued an 8-K filing on December 13, 2017, announcing updates to its financial guidance. The company reaffirmed its financial expectations for the remainder of the decade and provided initial financial guidance for fiscal year 2018. This report highlights Lilly's proactive approach to investor communication, offering insights into its anticipated performance and strategic outlook. The filing also details Lilly's use of non-GAAP financial measures, which exclude items like amortization of intangibles and other highly variable or unpredictable expenses. The company asserts that these adjusted measures provide a clearer view of ongoing operations and facilitate more meaningful comparisons over time, aiding investors in evaluating operational trends that might otherwise be obscured. Management also utilizes these non-GAAP metrics for internal performance evaluation and resource allocation.

Key Highlights

1Eli Lilly (LLY) issued an 8-K on December 13, 2017, updating financial guidance.
2Company reaffirmed financial expectations through the end of the decade.
3Initial financial guidance for the fiscal year 2018 was provided.
4A teleconference was held to discuss the financial guidance with analysts and media.
5The filing emphasizes the use of non-GAAP financial measures.
6Non-GAAP measures exclude amortization of intangibles and other variable/unpredictable items.
7Lilly believes non-GAAP measures offer investors a better understanding of ongoing operations and trends.

ELI LILLY & Co 8-K Report, Financial Results (Dec 13, 2017)

Summary

Key Highlights

Frequently Asked Questions